- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
FDA clears first-in-class high cholesterol drug
Treatment is first non-statin LDL-C lowering treatment approved in years.
A first-in-class, non-statin drug to lower cholesterol will soon be on the market after receiving FDA approval
The agency cleared bempedoic acid (Nexletol, Esperion), an oral, once-daily, non-stain, LDL-Cholesterol lowering medication. The drug is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver, Esperion said in a press release.
Related: Top 3 Drugs Expected In First Half 2020
Nexletol is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C.
It is the first oral, once-daily, non-statin LDL-C lowering medicine approved since 2002 for indicated patients, Esperion said. It will be on the market on March 30.
“Nexletol delivers upon a commitment we’ve made to millions of patients for a new treatment alternative if they struggle with bad cholesterol and have ASCVD or HeFH,” says Tim Mayleben, president and CEO of Esperion. “Even with maximally tolerated statins, which may mean no statin at all, some of these patients can’t achieve their LDL-C goals.”
Related: FDA Okays New Indication For Fish Oil Drug
Despite standard of care treatments, including statin therapy, it is estimated that nearly 15 million patients in the US cannot achieve guideline recommended LDL-C levels, according to Esperion.
The approval of Nexletol is supported by a global pivotal Phase 3 LDL-C lowering program conducted in more than 3,000 patients. Nexletol provided an average of 18% placebo corrected LDL-C lowering when used with moderate or high intensity statins.
Esperion said it is working with health insurance providers to “help ensure broad insurance coverage and patient access to Nexletol.” Plus, it is committed to achieving the lowest branded tier coverage for Medicare patients.
Read more: Blockbuster Diabetes Drug Snags New Heart Indication
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
